Introduction {#S1}
============

Recent advances in the management of vertigo and tinnitus focus on device-related modalities that provide some patients with aural symptoms with acceptable results [@R01], but others with less positive ones [@R02]. There is therefore an increasing interest for pharmacological interventions that are traditionally used to treat various inner ear diseases and that are particularly effective in controlling symptoms if prescribed at higher dosages than in the past [@R03] and/or as add-on medication in multi-component therapy [@R04]. Finally, there is accumulating evidence that drugs approved for use in other diseases can be prescribed \"off-label\" to patients affected by inner ear dysfunctions with satisfactory results [@R05]. For example, the 1-4 dihydropyridine calcium channel blocker nimodipine (NMDP) is approved by the Food and Drug Administration for reducing vasospasm after subarachnoid haemorrhage and neurological conditions [@R06]. Initially developed to treat high blood pressure, NMDP was more recently suggested to be an effective countermeasure for labyrinthine dysfunction [@R07] [@R08], dizziness due to central nervous system disorders [@R09] and migraine-related vertigo [@R10]. It has also been shown to prevent reduction of cochlear blood flow of different origins [@R11] [@R12], and represents a potential therapeutic option for at least some types of tinnitus [@R13] [@R14]. Recent experience has shown that NMDP reduces the calcium intracellular overload in traumatised neurons so to exert an anti-apoptotic effect and improves the rate of nerve collateral re-sprouting, axonal growth and re-myelination of injured cranial nerves [@R15] [@R16]. Accordingly, its use in the prophylaxis and/or reparation of nerve damage occurring during head and neck surgery has been proposed [@R17] [@R18]. Despite this accumulating experimental and clinical evidence, which could potentially expand the prescription of NMDP in otolaryngology, its use in clinical practice is far from widespread. This manuscript: (a) briefly summarises the nature and function of calcium channels with particular attention to their role in auditory and vestibular systems; (b) reports on the experimental findings regarding the application of NMDP in inner ear function and dysfunction; and (c) reviews the evidence that suggest further indications for NMDP both as a single strategy or as an adjunct to standard care in otolaryngology.

Calcium channels: basic concepts {#S2}
================================

Voltage-gated calcium channels (VGCCs) are a group of ion-conducting pores located in the plasma membrane of excitable cells (e.g., muscle, glial cells, neurons, etc.) with a selective permeability to the calcium ion (Ca^2+^). They belong to a large family of transmembrane ion channels that also include voltage-gated sodium, barium and potassium channels [@R19]. At resting membrane potential, VGCCs are normally closed and the concentration of Ca^2+^ is much higher outside of the cell than inside. In response to depolarisation, VGCCs allow Ca^2+^ to enter the cell and promote exocytosis which, depending on the cell type, results in activation of calcium-sensitive potassium channels, neurotransmitter and hormone release, muscular contraction, excitation of neurons and gene expression. The slow decline of cytoplasmic Ca^2+^ concentration after its initial rise to a peak level is due to both an increase of ion extrusion through a Na^+^Ca^2+^ exchange system at the plasma membrane and to reuptake into internal organelles.

Malfunction of VGCCs can lead to an excess of intracellular calcium that over-activates enzymes such as nucleases [@R20] and phospholipases [@R21] causing DNA injury and breakdown of phospholipids, respectively, which in turn irreversibly damage the membrane causing cellular death. VGCCs are complex proteins composed of distinct subunits (α1, α2δ, β1-4, and γ) ([Fig. 1](#F1){ref-type="fig"}). The α1 subunit with a mass of 190 to 250 kDa is the largest. It represents the primary subunit that forms the ion conducting pore necessary for channel functioning, determines most of the channel voltage-dependent opening and closing behaviours and contains the drug/toxin-binding sites. It is encoded by at least 10 different genes in mammals. It consists of four homologous (I-IV) domains containing six transmembrane α-helices each (S1-S6) [@R22]. The other subunits only exert an auxiliary modulation of the pharmacological and electrophysiological properties of VGCCs [@R23].

![A) Calcium channel structure comprising the α1, α2δ, β, and, γ subunits. The α1 subunit, represented here with its 4-fold monomeric structure, is responsible for many of the functional characteristics of these channels, including the pore voltagedependent gating and dihydropyridine binding. The α2 is the extracellular glycosylated subunit that interacts with the α1 subunit. The δ subunit has a single transmembrane region with a short intracellular portion that serves to anchor the protein in the plasma membrane. The β subunit is the only Ca2+ channel subunit that is entirely cytoplasmic. The γ1 subunit is a glycoprotein that, for the most part, is not required to regulate the channel complex. B) The α1 subunit forms the Ca^2+^ selective pore, which contains voltage-sensing apparatus and drug/toxin-binding sites. This subunit contains 4 homologous domains (labelled I--IV), each containing 6 transmembrane helices (S1--S6).](0392-100X-35-135-g001){#F1}

Multiple types of Ca^2+^ channels are known and are classified according to differences in ionic conductance, gating modality and pharmacology. For instance, it was initially observed that most calcium channels need strong depolarisation for opening and are thus are defined \"high-voltage activated channels\"; on the other hand, only a minority are activated by weak depolarisation and are referred to as \" low-voltage activated channels\" [@R24]. A further alphabetical nomenclature was proposed for different types of calcium currents [@R25]. For instance, most VGCCs are termed L-type because they inactivate slowly (\"long-lasting\"), need strong depolarisation to activate and are blocked by organic L-type calcium channel antagonists, such as the dihydropyridines nifedipine and NMDP [@R26]. They are heterotetrameric polypeptide complexes comprising the α1, α2δ, β, and, in some tissues, γ subunits. The α1 subunit is encoded by CACNA1S, CACNA1C, CACNA1D and CACNA1F genes. Deficiency in 1D subunit of L-type Ca^2+^ channels causes the absence of L-type Ca^2+^ currents in cochlear inner hair cells and leads to degeneration of both outer and inner hair cells, with subsequent congenital deafness in the mouse [@R27].

Recently, a mutation in CACNA1D, which encodes for the pore-forming α1 subunit of Ca(v)1.3 L-type calcium channel, has been identified in two consanguineous families with deafness. All deaf subjects also showed pronounced sinoatrial node dysfunction at rest [@R28]. Auditory sensory hair cells of most species prevalently have L-type calcium channels.

P/Q-type calcium channels are present in Purkinje neurons in the cerebellum (and thus the name) and in cerebellar granule neurons. They are presynaptic high-voltagegated calcium channels that couple neuronal excitation to release of neurotransmitter. The α1 subunit is encoded by the CACNA1A gene and multiple splice variants exist in the central nervous system. Malfunction of P/Q channels due to mutations are probably associated with familial hemiplegic migraine type 1. In the mammalian auditory system, P/Q voltage-gated calcium channels modulate transmitter release at the olivo-cochlear efferent-inner hair cell cholinergic synapses, but their involvement in hearing defects is not known.

N-type (\'N\' for \"Neural-Type\") Ca^2+^ channels are highvoltage activated calcium channels present throughout the central and peripheral nervous systems at presynaptic terminals. The α1 subunit is encoded by CACNA1B gene. N-type voltage-gated calcium channels, as well the P/Q type are responsible for the synaptic activation of the inhibitory auditory efferent system.

The R-type calcium channel is a unique subtype of VGCC as its electrophysiological properties are intermediate between those of typical high-voltage-activated (P/Q-type, N-type, and L-type) or low-voltage-activated (T-type) channels. R-type channels are also typically resistant (thus the name) to antagonists of L-, N-, and P/Q-type Ca^2+^channels. They have been identified in various areas of the CNS such as the cortex, hippocampus, striatum, amygdala, and interpeduncular nucleus and their role is believed to be predominantly implicated in spatial memory, fear behaviour, pain perception and morphine analgesia. The α1 subunit is encoded by CACNA1E gene. Finally, T-type calcium channels are distinguished from other VGCCs by their low voltage thresholds for activation and inactivation. \"T\" stands for transient, referring to the length of activation. In many neurons, cytosolic Ca^2+^ influx through LVA channels triggers low-threshold spikes, which in turn trigger a burst of action potentials mediated by Na^+^ channels. T-type calcium channels contribute to the pacemaker activity of the sinoatrial node of the heart. The α1 subunit is encoded by the CACNA1L gene.

A further classification of calcium channels was proposed in 2000 [@R29], based on the chemical symbol of the ion (Ca), with the principal physiological regulator (voltage) indicated as a subscript (Cav). The Ca~v~1 subfamily (Cav1.1 to Cav1.4) includes L-type calcium channels. The Cav2 (Cav2.1 to Cav2.3) includes P/Q-, R-, N-type calcium channels and the subfamily Cav3 (Cav3.1 to Cav3.3) identifies T-type calcium channels. The aforementioned main biochemical properties of VGCCs and their sensitivity to 1,4 dihydropyridine are summarised in [Table I](#T1){ref-type="table"}.

###### 

Classification of voltage-gated calcium channels (VGCCs).

Classification of voltage-gated calcium channels (Cav) according to alphabetical nomenclature, electrophysiological properties (HVA: high voltage activated, LVA: low voltage activated), genetic determinants and dihydropyridine (DPH) sensitivity.

  -----------------------------------------------------------------------------------------------
  Type                        Voltage        α~1~ subunit (gene) Chromosome   DPH sensitivity
  --------------------------- -------------- -------------------------------- -------------------
  L-type calcium channel      HVA            Cav1.1 (*CACNA1S*) 1q32\         Blocked
                                             Cav1.2 (*CACNA1C*) 12p13.3\      
                                             Cav1.3 (*CACNA1D*) 3p14.3\       
                                             Cav1.4 (*CACNA1F*) Xp11.23       

  P/Q-type calcium channels   HVA            Cav2.1 (*CACNA1A*) 19p13         Resistant

  N-type calcium channel      HVA            Cav2.2 (*CACNA1B*) 9q34          Resistant

  R-type calcium channel      Intermediate   Cav2.3 (*CACNA1E*) 1q25.3        Resistant

  T-type calcium channel      LVA            Cav3.1 (*CACNA1G*) 17q22\        Partially blocked
                                             Cav3.2 (*CACNA1H*) 16p13.3\      
                                             Cav3.3 (*CACNA1L*) 22q13.1       
  -----------------------------------------------------------------------------------------------

Calcium channels in the auditory and vestibular systems {#S3}
=======================================================

The free intracellular concentration of calcium (Ca^2+^) in hair cells is very low at rest, but it rapidly increases due to entry through clusters of VGCCs in response to acoustic stimulation, which primarily allow the entry of cations close to the stereociglia tips at the cellular apex. The calcium release from intracellular stores (endocytosis) is actually considered less relevant in this process. Calcium promotes vesicles fusion with the presynaptic membrane, leading to neurotransmitter release at the baso-lateral cellular wall [@R30], in order to activate auditory nerve terminals and generate action potential firing patterns. Hair cells, as retinal bipolar cells and photoceptors, contain ribbon-type active zones. The synaptic ribbons are plate-like, proteinaceous structures packed with synaptic vesicles. The \"ribbon\" or \"dense body\" anchors to the presynaptic membrane only nanometres away from the clustered VGCCs ([Fig. 2](#F2){ref-type="fig"}). Ribbons are thought to maintain exocytosis and sustained neurotransmitter release, albeit at reduced rates, in response to prolonged sound stimuli [@R31]. The intracellular spread of Ca^2+^ in hair cells is limited by the endogenous buffering activity of the cytosol. This system incorporates endogenous fixed and mobile Ca^2+^ buffers that limit the spread of free calcium in hair cells and carry incoming Ca^2+^ away from synaptic areas [@R32]. A plasma membrane Ca^2+^-ATPase type 2 pump is responsible for extrusion of calcium from mammalian hair cells and its central role in intracellular calcium homeostasis is revealed by the hearing loss resulting from mutations in the plasma membrane CaATPase [@R33]. Moreover, calcium influx into hair cells and its growing concentration opens Ca^2+^-activated K^+^ channels. The outward K^+^ flow that follows repolarises the cell, closing Ca^2+^ channels and priming the cell for another cycle of oscillation. The number, distribution and kinetics of Ca^2+^ channels and K^+^ channels determine the characteristic frequency at which a hair cell specifically responds and represents the basic process of electrical tuning in lower vertebrates\' cochlea [@R34]. The presence of L-type channels is reported in the olivary nuclei, but they express a higher proportion of P/Q-type Ca^2+^ channels [@R35] [@R36] while T-type calcium channels are expressed in thalamic projection neurons to cortical auditory areas [@R37].

![A) schematic representation of cochlear hair cell structure with baso-lateral wall cytoplasmic membrane (marked with circle) and afferent auditory nerve bottoms; and B) presynaptic \"active zone\" with vesicles and ribbon containing neurotransmitters with clustered voltage-gated calcium channel (VGCCs).](0392-100X-35-135-g002){#F2}

The role of VGCCs in the vestibular end-organ is more debated. From animal experiments, it appears that the majority of VGCCs in semi-circular canals hair cells are L-type [@R38], although an R-type current component has been proposed based on its resistance to L- and N-type antagonists [@R39]. Furthermore, an antibody to N-type subunits labelled the baso-lateral membranes of type I and type II hair cells [@R40], but further evidence is needed. Similarly, the saccular region displayed at least two different type of calcium channels, including L-type, both inhibited by nifedipine and promoted by the calcium-channel agonist Bay K 8644 [@R41]. Besides this uncertainty, the mechanism of calcium sequestration for bio-crystallisation from endolymph through calcium pores is partially unknown, so that the formation and growth of otoconia remains to be elucidated [@R42]. In the brainstem, within the circuitry for the vestibulo-ocular reflex (VOR), neurons in the medial vestibular nucleus show adaptive changes in firing rate responses in relation to VOR gain (the ratio of evoked eye velocity to input head velocity). The firing rate response of neurons in the medial vestibular nuclei is reduced by increasing extracellular calcium and increased either by lowering extracellular calcium or with antagonists to calcium-dependent potassium channels [@R43]. L-, N- and Ttype calcium channels neurons are present in the medial vestibular nuclei [@R44] [@R45], but their specific contribution to vestibular-ocular reflex is not fully understood. The large amount of ion-gated channels in hair cells found in these experimental studies points to their likely relevant role in highly excitable cells of both the cochlea and the labyrinth, supporting the hypothesis that inner ear dysfunction as complex as Ménière\'s disease could be interpreted as channelopathy, particularly in those cases where familial expression of the disease is documented [@R46].

Nimodipine: from experimental data to clinical evidence {#S4}
=======================================================

NMDP is a calcium channel blocker (CCB) belonging to the dihydropyridine class and is a highly lipophilic agent that rapidly crosses the blood-brain barrier ([Fig. 3](#F3){ref-type="fig"}). Its mechanism of action is the selective blockage of intracellular calcium ions influx through L-type VGCCs. NMDP exerts a vasoactive effect by predominantly dilating small and collateral cerebral vessels, thus improving blood supply to hypo-perfused (post-ischaemia) areas and cerebral oxygenation even in healthy subjects [@R47]. In the inner ear, the perilymphatic perfusion of NMDP is known to suppress both spontaneous neural noise and compound action potential. These are reversible and dose-dependent effects and provide support for an exclusively presynaptic role of L-type Ca^2+^ channels in the regulation of both spontaneous and evoked neurotransmitter release from hair cells [@R48]. Similarly, the guinea pig compound action potential, the summating potential and the spontaneous firing of single cochlear ganglion neurons can be substantially reduced by the direct administration of NMDP in the cochlea [@R49]. Recent findings have shown that Deiter\'s cells in the cochlea not only provide hair cells with supporting activity, but also contribute to their electrical and biomechanical properties. It has been suggested that these cells modify cochlear dynamics by influencing the force produced by sound-induced motion of outer hair cells, depending on their large voltage-activated, outwardly K^+^ selective conductance. Even if voltage-activated Ca^2+^ currents are not present in Deiter\'s cells, NMDP interacts directly with K^+^ channels in a voltage dependent manner and potentially interferes with depolarisation of the organ of Corti [@R50]. The role of L-calcium channels in exerting presynaptic control on both acoustically provoked and spontaneous excitation of auditory nerve fibres appears to be of relevant interest since their abnormal function is suspected to be a potential source of annoying symptoms such as tinnitus [@R51]. The effect of selective Ca^2+^ channel agonists and antagonists on the afferent neuronal activity of isolated frog posterior semicircular canal is clearly documented [@R52] [@R53]; resting activity is substantially affected by all dihydropyridines, whereas only NMDP has been shown to significantly reduce the mechanically evoked activity [@R38]. In particular, the stronger inhibitory activity of NMDP compared with nifedipine, also observed in isolated hair cells of the cochlea [@R54], may be due to their different biophysical and conformation-dependent interactions with the L-type calcium channel. Their overlapping actions on resting discharge could depend on different enzymatic patterns involved in rest and mechanically-evoked stimulation [@R55]. Since the underlying pathogenic mechanism of Ménière\'s disease is an over-distension of the membranous structures of both the labyrinth and cochlea (endolymphatic hydrops) that modifies resting discharge of hair cells in the absence of sound stimuli and head movements, NMDP, cinnarizine and, partially, flunarizine qualify as a rational choice for this disease because of their selective activity on L-type calcium channels. The effects of mechanical over-stimulation of outer hair cells, such as that by acoustic trauma, results in excessive entry of Ca^2+^ in hair cells [@R56] and its sustained intracellular overload primarily activates complex enzymatic reactions, namely phospholipase A2, protein kinase II and nitric oxide synthase that subsequently cause degeneration of the phospholipids of the membrane, cellular lysis and death [@R57]. VGCCs are therefore supposed to be involved in the pathogenesis of acoustic injury in the auditory system as demonstrated by the recording of auditory brainstem responses (ABR) and morphological study of the cochlea in ddY mice after acoustic over-exposure [@R58]. Many experiments in animals have been carried out to test the hypothesis that NMDP and other L-type calcium channel blockers can protect hair cells from acoustic trauma, but the results are so far inconclusive [@R59]^-^[@R61]. In guinea pigs, cochlear blood flow (CBF) significantly decreases after administration of salicylate (100 mg/kg), but increases after administration of NMDP (2 mg/kg). After simultaneous administration of both salicylate (100 mg/kg) and NMDP (2 mg/kg), CBF remains unchanged. These results suggest that NMDP prevents the decrease in CBF induced by salicylate in animals [@R62], but no experimental data are available for human CBF in relation to administration of VGCCs blockers alone or in association with ototoxic drugs. In order to study the efficacy of calcium antagonists in vertebrobasilar insufficiency, an animal model of VBI was developed by occluding one vertebral artery with a balloon catheter. Judging by the reversal of the nystagmic pattern, the CCBs flunarizine and NMDP were suggested to be effective drugs in this animal model [@R63]. The protective effect of NMDP with respect to traumatic damage to the auditory nerve is documented by a recent study in rats [@R64]. The histological examination of the temporal bones of NMDPtreated animals revealed significant preservation of spiral ganglion cells in the basal turn of the cochlea in response to experimentally provoked compression of the cerebellopontine angle portion of the eighth nerve. In humans, a prospective, randomised, double-blind study to assess the intra-operative efficacy of diltiazem (a non-dihydropyridine member of the calcium channel blocker family commonly used to treat hypertension and angina pectoris) in preventing acoustic trauma during otologic surgery was carried out in 1995 [@R65]. The results were influenced by a small postoperative sensorineural hearing loss in all cases (treated and placebo) and by the tendency for better preservation of the bone-conduction hearing threshold in the therapy group, although this did not reach statistical significance. No further trials regarding this possible indication have been reported to date. On the other hand, prophylactic treatment with NMDP is definitively shown to be effective in reducing both facial and cochlear nerve damage in humans due to vestibular schwannoma surgery [@R17] [@R66]^-^[@R68] by improving axon regeneration and collateral sprouting. One study [@R17] showed that all patients who had received NMDP and hydroxyethyl starch-based prophylaxis had a significant recovery of facial nerve function (House-Brackmann Grade I-II) compared with preoperative staging (House-Brackmann Grade III or worse), whereas one third of patients with pre-operative facial nerve paresis (House-Brackmann Grade III or worse) who had not received such prophylactic treatment were unchanged at long-term follow-up post-operation. In addition, in more than 50% of patients undergoing surgical removal of vestibular schwannoma without prophylactic medication, intraoperative brainstem auditory evoked potentials monitoring showed a sudden or slowly progressive loss of potentials. Despite prompt initiation of intraoperative vasoactive treatment, preservation of hearing function could not be obtained, suggesting that prophylaxis is superior to intraoperative vasoactive treatment. In a recent experience, the resected recurrent nerve due to removal of a thyroid cancer was repaired with a nerve graft and the patient was further treated with nimodipine for 3 months. After therapy, the electromyography showed complete re-innervation of laryngeal muscles [@R18]. This experience suggests the potential utility of NMDP as add-on therapy to prevent and/or facilitate re-innervation of both superior and recurrent laryngeal nerve lesions that may occur during thyroid surgery [@R69] [@R70] or of other nerves that could be damaged during neck dissection [@R71]. The use of CCBs in the treatment of peripheral vertigo has been reported for many years in Europe [@R72] and their efficacy and safety has been tested in two double-blind studies that included different types of peripheral vestibular vertigo [@R08] [@R73]. In the first study, the effectiveness of NMDP (30 mg three times daily) was compared to cinnarizine (150 mg per day); after 12 weeks of treatment, the former drug reduced the incidence of moderate vertigo attacks to 78.8% of cases, and of severe vertigo in 85% of cases, whereas cinnarizine reduced 65.8% of moderate vertigo episodes and 89.8% of severe ones. Both NMDP and cinnarizine exhibited a significant therapeutic effect and similar safety profile. In the second study, conventional NMDP was administrated three times daily at a dosage of 30 mg in 26 patients and its effect compared to that of an extended release formulation (90 mg, once a day) in 25 patients. After 8 weeks of extended release drug treatment, about 90% of both vertigo disability and severity was rated as decreased by 50%. In the conventional group, rating of severity was reduced by 50% in 90% of patients after 8 weeks whereas vertigo disability was decreased by 50% in 64% of cases. No significant difference was found between groups and both drug regimens were considered effective and well tolerated. While the aforementioned studies investigated the effectiveness of NMPD in the treatment of miscellaneous peripheral vestibular disorders, only one pilot study specifically explored the beneficial use of NMDP as monotherapy in medical treatment of Ménière\'s disease [@R07]. NMDP was prescribed to Ménière\'s disease patients whose first-line medical treatment (diuretics, salt dietary restriction and vestibular suppressants) was not effective in controlling vertigo, or ameliorating or stabilising hearing loss. A recent retrospective analysis [@R14] of 10-year experience in the long-term management of patients affected by definite Ménière\'s disease, diagnosed according to the American Academy of Otolaryngology- Head and Neck Surgery Committee on Hearing and Equilibrium diagnostic guidelines, highlighted a specific effect of NMDP as an add-on therapy for cochlear dysfunction [@R74]. This study documented that a fixed combination of NMDP (at a dose of 40 mg a day) and betahistine (at a dose of 32 mg a day) for six months was more effective than monotherapy with betahistine (at a dose of 32 mg a day) for the same period in reducing the number of vertigo attacks, subjective annoyance due to tinnitus and severity of sensorineural hearing loss. These data suggest that NMDP should be prescribed as an add-on therapy in the long-term medical management of Ménière\'s disease in consideration of its efficacy on cochlear symptoms. This result confirms previous evidence on the beneficial effect of NMDP on tinnitus in both humans [@R13] and animal models [@R75]. Drug treatments are not commonly used for benign paroxysmal positional vertigo because different repositioning manoeuvres are now available to cure the unusual manifestations of otolith dysfunction [@R76] [@R77], but it could be speculated that CCBs offer an attempt to prevent flare-ups in patients who are also affected with other peripheral vestibulopathies [@R78].

![Chemical structure and formula of nimodipine. 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4- dihydropyridine-3,5-dicarboxylate C~21~H~26~N~2~O~7~.](0392-100X-35-135-g003){#F3}

Finally, in order to test the effect of NMDP on the haemorheology and brainstem auditory evoked potentials (BAEP) in patients with vertebrobasilar insufficiency (VBI), a pilot study on 50 cases was carried out [@R79]. Patients were divided into a NMDP group (25 cases) and a therapy- as-usual group (25 cases). Compared with the therapyas- usual group, plasma viscosity was markedly decreased (p \< 0.05) in the NMDP group, and peak latency of V wave, inter-peak latency of III-V and I-V were also improved significantly (p \< 0.05). It was therefore suggested that NMPN could ameliorate central auditory pathway function through its beneficial effect on haemorheology in patients with vertebrobasilar insufficiency. This study further confirms the possible role of nimodipine in vestibular disorders since it has been shown that vertigo may also arise from cerebellar and cerebral vascular diseases [@R80], as reported below.

Further strategies and applications {#S5}
===================================

Nimodipine and vertigo/dizziness of vascular origin {#S5a}
---------------------------------------------------

Vestibular compensation is a progressive neural process taking place in the central nervous system, which recalibrates vestibulo-oculomotor and vestibulo-spinal reflexes after peripheral vestibular-end organ failure and/or a vestibular (VIII nerve) neuritis. Its evolution is generally thought to be complete and recovery may be achieved in a relatively short time in most cases. However, some patients complain of residual symptoms such as postural instability and episodic vertigo for long periods of time.

A single cause for this delayed compensation process is seldom identifiable and a multifactorial pathogenesis is most likely. For example, persistent vertigo and dizziness are more frequently observed in patients with cerebrovascular disease affecting those specific central nervous system areas and neural pathways that are supposed to be directly involved in vestibular compensation [@R81]. Moreover, it has been largely confirmed that patients with balance and gait disorders have a higher incidence of MRI white matter hyper-intensities due to white matter ischaemic disease and hypertension, so that cerebrovascular disorders may account for persistent vertigo per se [@R82]. Since the beneficial effects of NMDP on age-related cerebrovascular disorders in animals [@R83] and in human clinical trials [@R84]^-^[@R86] are extensively documented, its use has been proposed in the treatment of vertigo in such patients. Interestingly, a study on elderly patients with chronic brain failure who received a single 30 mg oral dose of NMDP followed by two weeks treatment at a dose of 30 mg three times a day showed a significant amelioration of dizziness [@R87].

It should be added that both cerebrovascular diseases [@R88] and vertigo [@R89] are often associated with depression, a relevant cause of significant comorbidity. In a double-blind, randomised clinical trial [@R90], 101 patients diagnosed with \"vascular depression\" treated with fluoxetine at standard doses were randomised to placebo or NMDP administration. Treatment outcomes were assessed by the Hamilton Depression Rating Scale. Depression was decreased in both groups, but a greater improvement and a lower percentage of recurrence were seen in fluoxetine-NMDP patients. It should be added that in a previous multicentre, placebo-controlled, double-blind clinical study in 178 elderly patients with cognitive decline [@R91], NMDP alone seemed to exert an antidepressant effect. Unfortunately, the exact mechanism of the probable antidepressant action of NMDP is unclear.

Finally, unlike other calcium channel blockers, NMDP can also modulate other calcium-dependent processes such as acetylcholine release, which is potentially of benefit in improving vestibular compensation in the elderly affected by uncompensated peripheral vestibular disorders and mild cognitive impairment due to cerebrovascular diseases [@R92].

All these results clearly suggest a potential effect of NMPD in the pharmacological treatment of patients with uncompensated peripheral associated with cerebral vascular diseases presenting with persistent and recurrent dizziness. This indication seems to be most relevant in dizzy patients, and the elderly in particular, who are also affected by mood disturbance. Further investigations with appropriate study-designs are needed.

Nimodipine and vestibular migraine {#S5b}
----------------------------------

Vestibular migraine (VM), also known as migraine-associated vertigo, is a common cause of dizziness in the adult population [@R93] [@R94], but in a large percentage of patients with vertigo, VM is under-diagnosed. Symptoms include spontaneous and positional vertigo, light-headedness and unsteadiness of variable duration, ranging from seconds to days. Some patients report a temporal relationship with the headache episode, but most do not. The wide variability in clinical presentation of patients with VM, lack of a generally accepted pathophysiologic model linking migraine and vertigo and the absence of specific biomarkers for the disease underlie the lack of commonly used criteria for diagnosis [@R95]. A recent classification of vestibular migraine [@R96] postulates that a diagnosis of VM must be formulated on the basis of the following criteria:

-   at least 5 episodes with vestibular symptoms of moderate or severe intensity, lasting 5 min to 72 hours;

-   current or previous history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD);

-   one or more migraine features with at least 50% of vestibular episodes:

    -   headache with at least two of the following characteristics:

        -   one sided location, pulsating quality, moderate or severe pain intensity, aggravation by routine physical activity;

        -   photophobia and phonophobia;

        -   visual aura;

-   not better accounted for by another vestibular or ICHD diagnosis.

Unfortunately, no standard medical treatment for acute attacks of VM is available, whereas prophylactic medications have been proposed.

A review of the pharmacological treatments of VM showed that common drugs routinely used in migraine prophylaxis (triptans, CCBs, nortriptyline, or metoprolol) can also be successfully prescribed to patients with VM [@R97]. This finding has been recently confirmed by a retrospective analysis of \'epigone\' migraine vertigo, a type of vertigo, migrainous in origin, starting late in lifetime and replacing, as an equivalent, a pre-existing migraine headache [@R98]. This study reported successful results in the prophylaxis of both headache and vertigo spells after the administration of flunarizine. In addition, emerging clinical evidence supports not only a strong association between migraine and Ménière\'s disease [@R99], but also clearly indicates that patients with episodic vertigo, fluctuating hearing loss and migraine respond better to CCBs than to anti-hydropic drugs [@R100] [@R101].

The efficacy of NMDP in prophylaxis of migraine has been extensively investigated, but the results of placebocontrolled trials are controversial. Three of six comparative trials with placebo suggested no significant difference [@R102]^-^[@R104], while the remaining three reported relatively large and statistically significant treatment effects [@R105]^-^[@R107]. This discrepancy could be due to many factors such as different types of migraine/headache included in the studies, dosages and duration of treatments and outcome measures used.

Taken together, these observations suggest an expanding indication for the use of NMDP in VM, but its potential efficacy needs to be documented in clinical trials with adequate study design.

Conclusions {#S6}
===========

The L-type calcium channel blocker NMDP has been widely utilised in numerous experimental and clinical investigations, far beyond its internationally approved indication. Primarily due to its vasoactive and neuroprotective effects on both the inner ear and the brain, it may be beneficial in many otoneurological syndromes, both peripheral, central and mixed, as monotherapy or as an add-on therapy to standard regimens. Its greater efficacy on aural symptoms such as tinnitus and hearing loss, if prescribed in association to betahistine compared to betahistine alone in the treatment of Ménière\'s disease, should be considered by otolaryngologists and audiologists and included in their routine pool of possible medications.

Since cerebrovascular lesions often cause gait disturbances and dizziness, and represent a possible cause of un uncompleted compensation of vestibular end-organ diseases, NMDP, by facilitating perfusion and oxygenation of human brain hypoxic areas, appears to be a rational choice in the treatment of vertigo of vascular origin. Despite existing uncertainties about the origin of vestibular migraine, it has been recently confirmed that patients suffering from this disease can be successfully treated with anti-migraine drugs so that NMDP may be an effective medical option considering both its efficacy as a migraine prophylactic drug and activity in inner ear disorders.

A more restricted field of application for NMDP is the surgery of the eighth nerve and cerebello-pontine angle lesions because of its neuroprotective effects, which are useful in preventing damage to both facial and cochlear nerves. It should be finally noted that despite increasing indications for the use of NMDP in otolaryngology, its prescription is still off-label in this field and informed consent should be obtained by patients before use.
